| Returns | 1W : -0.5% , 1M : -4.2%,1Y : 190% |
| LT : |
Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
| ST : |
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
| Peers & Returns | 1W | 1M | 1Y |
| MARKSANS PHARMA LTD | -0.5% | -4.2% | 190% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -1.1% | 0.1% | 30.6% |
| DR REDDYS LABORATORIES LTD | -0.4% | -3.6% | 65.1% |
| DIVIS LABORATORIES LTD | -0.6% | -3.9% | 94.4% |
| CIPLA LTD | 0.8% | -2% | 72.3% |
| BIOCON LTD | -12.3% | -18.6% | 51% |
| AUROBINDO PHARMA LTD | 0.8% | 3.8% | 81.4% |
| LUPIN LTD | 1.6% | 12.1% | 44.7% |
| TORRENT PHARMACEUTICALS LTD | 2.1% | -3.9% | 37% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
19.76
P/E Calculated based on EPS of 2.86
[ Mar2020 - Consolidated Results ] 3.64
P/B Calculated based on Book Value of 15.54
[ Mar2020 - Consolidated Results ] 1.91
P/S Calculated based on Revenues of 1210.55 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-18% -15% 3% |
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
